SELLAS Life Sciences Group, Inc. (SLS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
7 Times Square
New York, NY 10036
United States of America (the)
Phone
646 200 5278
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
March 12, 2008
| Name | Title | Pay | Year Born |
| Angelos Stergiou | Founder, President, Chief Executive Officer & Director | 1.07M | 1976 |
| John Thomas Burns | Senior Vice President & Chief Financial Officer | 630,592 | 1985 |
| Dragan Cicic | Senior Vice President & Chief Development Officer | 662,734 | 1963 |
| Andrew Elnatan | Senior Vice President of Regulatory Affairs, CMC & Quality | 0 | N/A |
| Stacy Yeung | VP, General Counsel & Corporate Secretary | 0 | N/A |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.